Compare Suven Life Sciences with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE SCIENCES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SCIENCES CADILA HEALTHCARE SUVEN LIFE SCIENCES/
CADILA HEALTHCARE
 
P/E (TTM) x -91.3 34.7 - View Chart
P/BV x 1.4 6.1 23.5% View Chart
Dividend Yield % 1.6 0.6 282.7%  

Financials

 SUVEN LIFE SCIENCES   CADILA HEALTHCARE
EQUITY SHARE DATA
    SUVEN LIFE SCIENCES
Mar-19
CADILA HEALTHCARE
Mar-20
SUVEN LIFE SCIENCES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs338352 95.9%   
Low Rs169207 82.0%   
Sales per share (Unadj.) Rs52.1139.2 37.4%  
Earnings per share (Unadj.) Rs6.811.8 58.1%  
Cash flow per share (Unadj.) Rs8.618.6 46.2%  
Dividends per share (Unadj.) Rs1.503.50 42.9%  
Dividend yield (eoy) %0.61.3 47.2%  
Book value per share (Unadj.) Rs65.3101.4 64.4%  
Shares outstanding (eoy) m127.281,023.74 12.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.92.0 242.4%   
Avg P/E ratio x37.123.7 156.3%  
P/CF ratio (eoy) x29.615.0 196.6%  
Price / Book Value ratio x3.92.8 140.9%  
Dividend payout %22.029.8 73.8%   
Avg Mkt Cap Rs m32,272286,033 11.3%   
No. of employees `0001.113.4 8.1%   
Total wages/salary Rs m66124,145 2.7%   
Avg. sales/employee Rs Th6,132.210,632.7 57.7%   
Avg. wages/employee Rs Th611.11,801.2 33.9%   
Avg. net profit/employee Rs Th803.5898.5 89.4%   
INCOME DATA
Net Sales Rs m6,635142,531 4.7%  
Other income Rs m2421,139 21.3%   
Total revenues Rs m6,877143,670 4.8%   
Gross profit Rs m1,60424,198 6.6%  
Depreciation Rs m2216,965 3.2%   
Interest Rs m383,418 1.1%   
Profit before tax Rs m1,58714,954 10.6%   
Minority Interest Rs m0288 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7183,198 22.5%   
Profit after tax Rs m86912,044 7.2%  
Gross profit margin %24.217.0 142.4%  
Effective tax rate %45.221.4 211.5%   
Net profit margin %13.18.5 155.1%  
BALANCE SHEET DATA
Current assets Rs m6,23287,154 7.2%   
Current liabilities Rs m1,49082,694 1.8%   
Net working cap to sales %71.53.1 2,284.0%  
Current ratio x4.21.1 396.8%  
Inventory Days Days8671 121.0%  
Debtors Days Days8394 88.1%  
Net fixed assets Rs m4,043133,236 3.0%   
Share capital Rs m1271,024 12.4%   
"Free" reserves Rs m8,183102,733 8.0%   
Net worth Rs m8,310103,757 8.0%   
Long term debt Rs m1832,146 0.1%   
Total assets Rs m10,389236,866 4.4%  
Interest coverage x43.15.4 802.0%   
Debt to equity ratio x00.3 0.7%  
Sales to assets ratio x0.60.6 106.1%   
Return on assets %8.76.5 133.8%  
Return on equity %10.511.6 90.1%  
Return on capital %19.513.7 142.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m5,62252,752 10.7%   
Fx outflow Rs m1,79914,504 12.4%   
Net fx Rs m3,82238,248 10.0%   
CASH FLOW
From Operations Rs m35625,054 1.4%  
From Investments Rs m-279-10,123 2.8%  
From Financial Activity Rs m-225-10,942 2.1%  
Net Cashflow Rs m-1483,989 -3.7%  

Share Holding

Indian Promoters % 63.4 74.8 84.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.0 8.3 -  
FIIs % 0.0 5.9 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 11.0 331.8%  
Shareholders   37,287 44,069 84.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE SCIENCES With:   FDC  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC  

Compare SUVEN LIFE SCIENCES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY20); Net Profit Down 79.3% (Quarterly Result Update)

Nov 15, 2019 | Updated on Nov 15, 2019

For the quarter ended September 2019, CADILA HEALTHCARE has posted a net profit of Rs 829 m (down 79.3% YoY). Sales on the other hand came in at Rs 34 bn (up 13.7% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SCIENCES SHARE PRICE


May 14, 2021 (Close)

TRACK SUVEN LIFE SCIENCES

  • Track your investment in SUVEN LIFE SCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON SUVEN LIFE SCIENCES

SUVEN LIFE SCIENCES 8-QTR ANALYSIS

COMPARE SUVEN LIFE SCIENCES WITH

MARKET STATS